How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/unresectable-locally-advanced-or-metastatic-cholangiocarcinoma-with-fgfr2-fusion.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Truseltiq	INFIGRATINIB	Helsinn Hlthcare		Fibroblast growth factor receptor 2		2019-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Helsinn Hlthcare · 1 drug in Unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion:

Cite this brief

Drug Landscape (2026). Unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/unresectable-locally-advanced-or-metastatic-cholangiocarcinoma-with-fgfr2-fusion. Accessed 2026-06-10.

Unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing